Anthem allowed to move forward with PPO to EPO switch in California

A California judge denied a request for a restraining order which would have stopped Anthem from moving 500,000 customers to plans that only cover out-of-network charges in an emergency.

The Los Angeles Times reported Anthem gave customers until Dec. 15 to switch to another insurer before being automatically switched from a paid provider organization (PPO) plan to an exclusive provider organization (EPO) plan design. Santa Monica-based Consumer Watchdog claimed the notice didn’t clearly inform customers about how such a change would affect them.

The judge ruled the group and the Anthem customers it’s representing lacked standing to ask for a restraining order because they haven’t suffered losses on the policies.

Anthem applauded the decision, saying the case has no merit.

“Anthem Blue Cross is pleased with the court's decision and based on the facts in the case, we believe the decision is appropriate,” company spokesman Darrel Ng said.

Consumer Watchdog attorney Jerry Flanagan said the group isn’t dropping the case and will seek damages for Anthem customers who are hurt financially by the change in plan design. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.